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The Democratic Republic of Congo is a high-burden 
country for multidrug-resistant tuberculosis. Médecins 
Sans Frontières has supported the Ministry of Health in 
the conflict-affected region of Shabunda since 1997. In 
2006, three patients were diagnosed with drug-resistant 
TB (DR-TB) and had no options for further treatment. 
An innovative model was developed to treat these pa-
tients despite the remote setting. Key innovations were 
the devolving of responsibility for treatment to non-TB 
clinicians remotely supported by a TB specialist, use of 
simplified monitoring protocols, and a strong focus on 
addressing stigma to support adherence. Treatment was 
successfully completed after a median of 24 months. This 
pilot programme demonstrates that successful treat-
ment for DR-TB is possible on a small scale in remote 
settings.
KEY WORDS:  tuberculosis; multidrug-resistant tubercu-
losis; Democratic Republic of Congo; resource-limited
THE DEMOCRATIC REPUBLIC of Congo (DRC) 
is considered a high-burden country for multidrug-
  resistant tuberculosis (MDR-TB),1 but the capacity to 
diagnose and treat MDR patients is severely limited. 
Confl  ict has fuelled the disease outbreak by disrupt-
ing health care and drug supplies and causing forced 
displacements.2,3 Treatment for MDR-TB is highly 
specialised, complex and expensive, and whether it 
can be safely implemented in remote settings is un-
certain. We describe a pilot programme implemented 
in Shabunda, an isolated confl  ict-affected region of 
DRC, where treatment for drug-resistant TB (DR-TB) 
was integrated into the National TB Programme 
(NTP) on a small scale. 
Shabunda is located 340 km from the provincial 
capital of South Kivu, Bukavu, and the main channel 
of communication is by air. The roads are impassable 
and in an advanced state of disrepair, making trade 
diffi  cult and discouraging agricultural initiatives. The 
region has been affected by confl  ict since 1996,3 and 
Médecins Sans Frontières (MSF) intervened in 1997 
to restart health services in a destroyed hospital. Only 
one centre in the region, located in the general hospi-
tal, had the capacity to diagnosis and treat TB, and 
patients often had to walk up to 90 km to seek treat-
ment. In 2004, the DRC Ministry of Health (MoH) 
asked MSF to become involved in their NTP. Cohort 
results for the fi  rst year showed a treatment success 
rate of 79.7%, a death rate of 7.8%, a defaulter rate 
of 3.6% and a failure rate of 1.3%.
Despite these positive results, the health of three 
patients diagnosed in April 2006 did not improve de-
spite good adherence and human immunodefi  ciency vi-
rus negative status. All had received inadequate treat-
ment regimens at the time of their fi  rst diagnosis, and 
two had experienced treatment disruptions directly due 
to confl  ict. Standard treatment protocols at the time 
dictated that these patients be sent home in the ab-
sence of second-line drugs. However, two of the pa-
tients had already been turned out of their homes due 
to their illness; one patient was the sole care giver of 
two young children. The TB treatment team, unable 
to accept defeat, enrolled them once again on a Cate-
gory II regimen, again without result. Sputum sam-
ples were eventually exported to a regional laboratory 
for drug susceptibility testing (DST), and resistance to 
3–5 fi  rst-line drugs was confi  rmed for each patient. 
TREATMENT MODEL 
MSF operated out of a busy district hospital, support-
ing general medical and surgical care. Neither the MSF 
nor the MoH doctors were TB specialists, and none 
had experience in treating MDR-TB. They received 
support from an expert TB clinician based in Europe 
with whom they communicated by mobile phone. 
The advisor was responsible for making all regimen 
choices and guiding the management of severe side 
effects. A simplifi  ed protocol for monitoring was de-
veloped (Table 1). A key simplifi  cation was to reduce 
the frequency of culture monitoring in the continua-
tion stage of treatment from monthly to quarterly 
samples. Treatment regimen changes were to be made 
only in response to the second-line DST results or in 
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case of severe side effects. Simple tools were used for 
clinicians to triage potentially serious adverse effects 
that required consultation with headquarters. 
To ensure reliable culture results, sputum samples 
were exported to a reference laboratory in Antwerp, 
Belgium. Sputum smears were performed locally. Bio-
chemical tests were performed in Bukavu, 2 days’ 
travel from Shabunda by plane, boat and car. Radiol-
ogy was not available in Shabunda.
The initial treatment regimen was based on fi  rst-
line DST for two patients, and consisted of fi  ve 
s  econd-line drugs in the intensive phase of treatment, 
followed by four in the continuation phase. However, 
the NTP did not allow para-aminosalicylic acid (PAS) 
due to concerns regarding maintenance of the cold 
chain, and preferred a regimen with four second-
line drugs, together with pyrazinamide (PZA) and 
ethambutol (EMB); at the time, generic PAS that did 
not require cold chain was not available. The fi  nal 
accepted regimen consisted of kanamycin, levofl  ox-
acin, prothionamide, cycloserine, PZA and EMB in the 
intensive phase, which were continued for 4 months 
past culture conversion. The continuation phase was 
18 months and consisted of the same drugs without 
the injectable agent (kanamycin).
Treatment during the intensive phase took place in 
a hospital isolation ward. As all patients lived outside 
Shabunda, host families were needed to provide hous-
ing during the ambulatory phase of treatment. All 
drugs were delivered under directly observed treat-
ment (DOT) by a nurse. Intensive health education 
and adherence support, including food supplements, 
were provided. 
The patients’ treatment was further challenged by 
MSF’s decision to hand over the Shabunda project to 
the MoH 7 months after treatment initiation, as the 
security situation in the region had improved. The 
hospital director took over responsibility for treating 
minor-to-moderate side effects. One mobile MSF doc-
tor visited the project once a month until September 
2008 to follow up on patients and provide supervisory 
support. This doctor had previously been based in 
Shabunda and had the respect of patients and MoH 
staff. During his visits, he reviewed all patients to-
gether with the MoH doctor and treatment nurse, 
provided on-the-job training and assessed other pro-
grammatic aspects such as adherence, stigma, nutri-
tion needs, equipment and staff issues. In the fi  nal 
year of the programme, fl  ight restrictions meant that 
he could only visit every 3 months. 
In the MoH pharmacy MSF left a complete stock 
of all of the drugs needed to treat the three patients, 
including cimetidine, ibuprofen, promethazine, meto-
clopramide, oral potassium, loperamide, pyridoxine 
and amitriptyline, to complete treatment and manage 
side effects. There were no drug stock-outs; however, 
an extra delivery of PZA was organised when the 
NTP ran out of stock and had to borrow from the 
MDR-TB patients.
RESULTS 
All patients had persistent negative culture results af-
ter culture conversion in the intensive phase and at 
least 2–4 culture-negative results in the continuation 
phase (Table 2). Second-line DST determined that one 
patient was on a regimen consisting of three second-
line drugs during the intensive phase due to resistance 
to ethionamide, but no history of second-line drug use 
was recorded. Despite this suboptimal regimen, cul-
ture conversion occurred at month 2 and remained 
negative. One patient had delayed results from his ini-
tial DST, and was therefore started on an empiric reg-
imen. The results, when returned, suggested that he 
was resistant to all fi  rst-line drugs except rifampicin; 
however, this was not identifi  ed until he was late into 
the continuation phase. He therefore continued on the 
empiric MDR-TB regimen. Conversion took place at 
4 months; however, delay in receiving the sample at 
the reference laboratory in Antwerp meant that the 
patient remained on the intensive phase for 10 months 
instead of 8. This patient, although improved, retained 
a chronic cough. The treatment outcome for all pa-
tients was ‘treatment completed’, as the frequency of 
Table 1  Simplified protocol for treatment and monitoring*
Baseline patient examination
  1  Thorough history and clinical examination
  2  Psychosocial assessment with a focus on factors affecting 
adherence (e.g., living situation, substance use/abuse, 
psychosocial supports)
  3  Sputum smear, culture and drug susceptibility testing
 4  Blood  tests:
    i  Full blood count
   ii    Liver function (ALAT)
  iii   Renal function (creatinine)
  iv    HIV  test 
  5  Hearing assessment (clinical)
 6  Vision  testing 
 7  Weight
 8  Pregnancy  test
Clinical follow-up
  First month of treatment 
    1  Daily physician review: clinical follow-up—cough, fever, 
weight, sputum production, side effects
  Remainder of intensive phase 
    1  Twice weekly physician review
  2  Daily  nursing  review
 Continuation  phase
    1  Daily review with DOT worker
  2  Monthly  physician  review 
  Monitoring during treatment
    1  Sputum smear every month during treatment
    2  Culture monthly during intensive phase, starting at end of 
month 2 and then 3-monthly in the continuation phase
    3  Blood tests as required and
     i  Monthly creatinine and potassium during phase with 
injectable drug
    ii      Liver function test (ALAT) every 3 months if receiving 
pyrazinamide or if at risk of hepatitis
  4  Monthly  weight
* Chest X-ray was not available and was not used in the clinical follow up. 
ALAT = alanine aminotransferase; HIV = human immunodeficiency virus; 
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culture monitoring was not suffi  cient to meet the de-
fi  ned criteria for ‘cure’.4
Side effects experienced with treatment were mild 
to moderate. One patient had hypokalaemia during 
the intensive phase, which resolved with oral potas-
sium. Another experienced jaundice in the intensive 
phase, which resolved without having to stop treat-
ment. Three months before treatment completion, one 
patient experienced psychological symptoms, which 
resolved with antidepressants. Stigmatisation of pa-
tients by members of the host families and neighbours 
was a major issue throughout the course of illness; 
prompt educational interventions from the DOT nurse 
and a supportive head of family were instrumental in 
resolving these issues. 
A major challenge in the model was communica-
tion between the treating staff and headquarters. Stan-
dardised forms proved useful in maintaining an over-
view of treatment despite the frequent changeover of 
staff during the long treatment period. The forms, 
however, proved vulnerable to transcription errors. 
Direct communication from the reference laboratory 
to headquarters helped reduce the risk of miscommu-
nication on critical culture results. The availability of 
rapid DST and simplifi   ed methods to monitor re-
sponse would improve the feasibility of the model. 
CONCLUSION
We were able to demonstrate in a small pilot pro-
gramme that successful treatment of MDR-TB is possi-
ble even in isolated low-resource settings using a sim-
plifi  ed treatment protocol. Such integrated models of 
care will be needed as DRC and other countries intro-
duce new World Health Organization TB guidelines, 
which recommend early access to diagnosis and treat-
ment of drug-resistant TB for high-risk Category II pa-
tients. Key aspects of our programme included remote 
advice to non-specialist clinicians by a TB specialist, 
the support of a respected MSF doctor throughout 
treatment, simplifi  ed monitoring protocols and strong 
emphasis on addressing stigma. The long delay in start-
ing the programme and delayed receipt of DST results 
likely contributed to the less than complete clinical re-
covery of one patient despite the successful outcome. 
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La République Démocratique du Congo est un pays à 
fardeau élevé de tuberculose à germes multirésistants 
aux médicaments. Médecins Sans Frontières a apporté 
son soutien au Ministère de la Santé dans la région de 
Shabunda atteinte par les conflits depuis 1997. En 2006, 
le diagnostic de tuberculose à germes résistants (TB-
DR) a été porté chez trois patients qui n’avaient aucune 
possibilité de traitement ultérieur. On a élaboré un mo-
dèle innovateur pour traiter ces patients en dépit de leur 
situation éloignée. Les innovations-clé ont été de dé-
placer la responsabilité du traitement vers des cliniciens 
non-TB qui ont été soutenus à distance par un spécia-
liste TB, l’utilisation de protocoles simplifiés pour le suivi 
ainsi qu’une forte focalisation pour éviter la stigmatisa-
tion afin de renforcer l’adhésion thérapeutique. Le traite-
ment a été achevé avec succès après une durée médiane 
de 24 mois. Ce programme pilote démontre qu’un traite-
ment couronné de succès est possible pour la TB-DR à 
une petite échelle dans des contextes éloignés.
La República Democrática del Congo es un país con alta 
carga de morbilidad por tuberculosis multidrogorresi-
stente. Médicos Sin Fronteras ha apoyado al Ministerio 
de Salud desde 1997 en la región de Shabunda, afectada 
por el conflicto. En el 2006, se estableció el diagnóstico 
de TB farmacorresistente (TB-DR) en tres pacientes y no 
existía para ellos otra opción de tratamiento. Pese a su si-
tuación apartada, se concibió un modelo innovador con 
el propósito de ofrecer tratamiento a estos pacientes. 
Los aspectos más notorios del modelo consistieron en la 
transferencia de la responsabilidad del tratamiento a 
médicos que no eran expertos en TB que contaban con 
el apoyo distante de un especialista, el uso de protocolos 
simplificados de seguimiento y un interés esencial en re-
solver el problema del estigma a fin de reforzar el cumpli-
miento terapéutico. Tras un lapso mediano de 24 meses 
se completó exitosamente el tratamiento. Este programa 
piloto demuestra que es posible tratar eficazmente la 
TB-DR en pequeña escala en los entornos remotos.
RÉSUMÉ
RESUMEN